Cost-effectiveness analysis of three kinds of nucleoside analogues for chronic hepatitis B

Objective To investigate economic effects of three kinds of nucleoside analogues in treatment of chronic hepatitis B.Methods 268 cases were divided into three groups,ADV group with adefovir dipivoxil 10mg,ETV group with entecavir 0.5 mg, LdT group with telbivudine 600 mg.All the groups were administered once a day with a course of 48 weeks.Efficacy and adverse reactions were observed.Cost-effectiveness analysis was used.Results ETV group and LdT group were better than ADV group in terms of HBV-DNA negative conversion rate(P0.01),in HBeAg negative conversion rate and ALT normalization rate,three groups showed no statistically significant differences(P0.05),The adverse reactions of three groups had no significant difference(P0.05).The effectiveness ratio of ADV group,ETV group,LdT group was 115.38,156.51,96.98 respectively.Telbivudine was superior to adefovir dipivoxil and entecavir in terms of economics.Conclution Telbivudine group was the optimal solution for chronic hepatitis B.